Skye Bioscience announced that it will host a virtual KOL event entitled “Metabolic Rewiring with CB1 Inhibition” on Wednesday, July 24, 2024, at 9:00 AM ET. The KOL event will feature Louis J. Aronne, MD, FACP, Marcus DaSilva Goncalves, MD, PhD, Lee M. Kaplan, MD, PhD, and Beverly Tchang, MD, who will discuss the current treatment landscape for obesity, including the role of peripheral CB1 inhibition as a differentiated mechanism. The event will focus on the scientific rationale for Skye’s Nimacimab peripheral CB1 inhibitor, the clinical experience, and the Phase 2 study design for Nimacimab as a monotherapy and in combination with a GLP-1R agonist. Dosing for the Phase 2 trial is expected to begin in Q3 2024.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SKYE:
- Skye Bioscience Establishes Metabolic Clinical and Scientific Advisory Board to Support Development of Nimacimab
- Skye Bioscience initiated with a Buy at Craig-Hallum
- Skye Bioscience Board Reshuffle and Strategic Leadership Strengthening
- Skye Bioscience appoints Karen Smith to the Board
- Skye Bioscience Appoints Dr. Karen Smith to Board of Directors